A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

Sandra M. Swain, Sung‐Bae Kim, Javier Cortés et al. · The Lancet Oncology · 2013 · 1K citations · Full text

Medicine, Oncology, Pharmacology +16

Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer

Thuy Vu, François X. Claret · Frontiers in Oncology · 2012 · 607 citations · Full text

Medicine, Oncology, Pharmacology +16

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

Aron Goldhirsch, Richard D. Gelber, Martine Piccart et al. · The Lancet · 2013 · 501 citations

Medicine, Oncology, Breast Oncology +13

Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy

John Stagg, Sherene Loi, Upulie Divisekera et al. · Proceedings of the National Academy of Sciences · 2011 · 487 citations

Medicine, Immunology, Oncology +17

Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide–Based Vaccines

Mary L. Disis, Theodore A. Gooley, Kristine Rinn et al. · Journal of Clinical Oncology · 2002 · 425 citations

Life Sciences, Immunology, Oncology +17